ArticleNanoscale advances2019
Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells.
Article in Nanoscale advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona "variable".Nanoscale advances · 2023Article
- Gold nanoparticles in virus detection: Recent advances and potential considerations for SARS-CoV-2 testing development.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Microfluidic SERS devices: brightening the future of bioanalysis.Discover materials · 2022Review
- Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment.Pharmaceutics · 2021Review
- Lactoferrin-Bearing Gold Nanocages for Gene Delivery in Prostate Cancer Cells in vitro.International journal of nanomedicine · 2021Article
- The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting.Frontiers in pharmacology · 2021Review
- Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Expert opinion on therapeutic targetsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.